Anastasis Biotec Ltd

United Kingdom|Biotechnology

Overview

Executive Summary

Anastasis Biotec (ABL) is a biopharmaceutical company focused on developing disruptive therapeutic drugs in Oncology and Virology.

What do we do?

The Company has a proprietary protein drug delivery platform enabling drugs to enter cells and cross the blood-brain barrier. Based on this platform, Anastasis has two cancer drugs targeting two of the commonest cancer-causing mutations, p53 and NOTCH. The Company also has a COVID-19 therapeutic in development.

Our drug delivery platform

ABL can deliver proteins and peptides of pre-defined specificity and activity into cells and nuclei to achieve a specific and selective therapeutic effect using the Antennapedia drug-delivery platform.

The Antennapedia (ANTP) platform is the core of ABL’s business and is protected by international patents awarded to the Company.

Our products

The products are at different stages of development:

S4 (cancer drug targeting NOTCH mutations): IND-enabling studies and a Phase I trial
AB1 (cancer drug targeting p53 mutations): R&D and optimization of the manufacturing method
ABC (COVID-19 drug): a proof-of-concept

Notable achievements and highlights

In 2019, ABL was awarded an Innovate UK grant to conduct pre-clinical studies for S4.
ABL has granted and applied patents providing full freedom to operate both the platform technology and arising drugs.
ABL's research on AB1 has been selected for presentation at the ASCO Gastrointestinal Cancer Symposium in January 2022.
ABL is runner-up for the GIANT Health Events (2021) Beanstalk competition.

Problem and Solution

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.

Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.

Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.

Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.

Proin mollis, magna consequat placerat tempus, lectus dui porttitor augue, eget vulputate orci augue nec nisl. Integer sagittis vitae nibh vitae finibus. Vestibul

Open an account to get
access to more details

Market Opportunity

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.

Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.

Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.

Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.

Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed sed enim volutpat, malesuada metus ut, lobortis lectus. Sed vulputate fringilla justo, sed condimentum tellus fermentum sit amet. Pellentesque tempus elit id dapibus ornare. Phasellus accumsan suscipit elit. Donec eget libero eget neque cursus bibendum. Praesent lacinia felis et aliquam condimentum.

Open an account to get
access to more details

Competitive Advantage

Open an account to get
access to more details

Highlights and Achievements

Open an account to get
access to more details

See more exiting opportunities on CapitalHQ

Wholesale Investor

Wholesale Investor, with over 45,000 subscribers, is a leading private capital marketplace operating across Australia, Singapore, and the UK. It has a 15-year track record of connecting private market opportunities with HNW, professional, and family office investors. In just 4 years, our product...

Australia AUD

Fintech Series B+ Software-as-a-Service

PRIMAL ORGANIX

Primal Organix has created the world’s first botanically derived Terpene blended anti-anxiety health supplement that manages anxiety in minutes. Our purpose is to support positive mental ill-health and well-being in all human beings.

Australia AUD

Healthcare Series A

Sustainable Fintech Fund

Startupbootcamp, the #1 Accelerator in the world outside of the US, established in 2010, operates in 27 countries around the globe, has accelerated over 1600+ startups with a success rate of 76% remaining active, raised over $2.2B in total funding, a network of more than 300+ investors, 5000...

Australia AUD

Fintech Fund

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

New Zealand NZD

Biotechnology Series B+

Anastasis Biotec Ltd

Overview

Problem and Solution

Market Opportunity

Competitive Advantage

Highlights and Achievements